Dupilumab Approved for Young Children with Chronic Spontaneous Urticaria

The FDA has approved dupilumab (Dupixent) for children aged 2 to 11 years with chronic spontaneous urticaria (CSU) who remain symptomatic despite histamine-1 antihistamine therapy, expanding treatment options for this patient population. The decision is supported by Phase 3 LIBERTY-CUPID trial¹ datademonstrating improvements in itch severity and urticaria activity, along with a well-established safety profile.

With this decision, dupilumab becomes the first biologic therapy approved in the United States for young children with uncontrolled CSU, a chronic inflammatory skin condition characterized by recurrent hives and severe itching that can significantly impact quality of life.

Addressing Unmet Need in Pediatric CSU

CSU is driven in part by type 2 inflammation and is typically managed with antihistamines. However, a subset of pediatric patients continues to experience persistent symptoms despite standard treatment. Estimates suggest that thousands of children in the United States fall into this category, highlighting a gap in effective therapeutic options.

For these patients, symptoms such as unpredictable itching and hives can interfere with sleep, daily activities, and overall well-being. The newly expanded indication introduces a targeted biologic option for a population that has historically had limited alternatives.

Clinical Evidence From LIBERTY-CUPID Program

The approval is based primarily on data from the Phase 3 LIBERTY-CUPID

clinical trial program, which evaluated dupilumab across multiple studies, including Study A, Study B, Study C, and the pediatric-focused CUPIDKids trial.

In the placebo-controlled Study A and Study C trials, dupilumab demonstrated statistically significant reductions in itch severity and overall urticaria activity at 24 weeks compared with placebo in patients aged 6 years and older. These studies also showed improvements in disease control, including higher rates of well-controlled disease and complete response.

The CUPIDKids study, a single-arm Phase 3 trial in children aged 2 to 11 years, provided pharmacokinetic and safety data supporting use in the younger population. Safety findings were consistent with the known profile of dupilumab across dermatologic indications, with injection site reactions being the most commonly reported adverse event. No new safety signals were identified in pediatric patients.

Mechanism Targets Type 2 Inflammation

Dupilumab is a fully human monoclonal antibody that inhibits signaling of interleukin (IL)-4 and IL-13, two key drivers of type 2 inflammation. By targeting these pathways, the therapy addresses underlying inflammatory mechanisms rather than only treating symptoms.

Expanding Role Across Immunological Diseases

The CSU approval represents another expansion of dupilumab’s role across diseases driven by type 2 inflammation. The therapy is already approved for multiple indications, including atopic dermatitis, asthma, and eosinophilic esophagitis, among others.

Globally, dupilumab has been approved in more than 60 countries and has been used in over one million patients across indications. Ongoing clinical development continues to evaluate its potential in additional inflammatory and allergic conditions.

Outlook for Treatment Landscape

The approval marks a shift toward targeted biologic therapies in pediatric dermatology and immunology, particularly for conditions where conventional treatments fail to achieve adequate disease control. As biologics continue to expand into younger patient populations, long-term safety, accessibility, and integration into treatment algorithms will remain key considerations.

References

1. Dupilumab for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine and Who Are naïve to, Intolerant of, or Incomplete Responders to Omalizumab (LIBERTY-CSU CUPID). National Library of Medicine. ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT04180488
2. Maurer, M., Casale, T.B., Saini, S.S., et al. (2024 Jul). Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): Two randomized, double-blind, placebo-controlled, phase 3 trials. Journal of Allergy and Clinical Immunology. https://doi.org/10.1016/j.jaci.2024.01.028